Role of the hematopoietic cytokines SCF,IL-3,GM-CSF and M-CSF in the diagnosis of pancreatic and ampullary cancer

Abstract

Background

Previous studies have demonstrated altered levels of hematopoietic cytokines in the serum of patients with different types of cancer.

Methods

We measured the serum levels of the hematopoietic cytokines stem cell factor (SCF), interleukin 3 (IL-3), macrophage-colony stimulating factor (M-CSF) and granulocyte-macrophage-colony stimulating factor (GM-CSF) in 40 pancreatic and ampullary cancer patients and 40 healthy volunteers, using ELISA. We also assessed the most widely used pancreatic tumor markers, carbohydrate antigen 19–9 (CA 19–9) and carcinoembryonic antigen (CEA), in both groups. We then correlated the concentrations of the cytokines and the tumor markers in the patients’ serum and we estimated their diagnostic ability by calculating diagnostic sensitivity and specificity, positive and negative predictive values and the receiver operating characteristic (ROC) curve.

Results

The SCF and IL-3 levels were significantly lower and the M-CSF levels significantly higher in pancreatic cancer patients than in controls. There were significant positive correlations between the serum levels of CEA and M-CSF, GM-CSF and SCF, and between GM-CSF and IL-3. The area under the ROC curve and diagnostic sensitivity of M-CSF were greater than those of SCF and IL-3. The diagnostic sensitivity of the combined use of SCF and M-CSF reached 97.5%.

Conclusion

The diagnostic ability of M-CSF and SCF in pancreatic and ampullary cancer should stimulate further studies evaluating their clinical usefulness as tumor markers.

Keywords

Hematopoietic cytokines Pancreatic cancer Ampullary cancer

References

Jemal

, Siegel

, Ward

, Hao

, Xu

, Thun

M.J.

. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225–49.

Jemal

, Siegel

, Xu

, Ward

. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277–300.

Decker

G.A.

, Batheja

M.J.

, Collins

J.M.

. Risk factors for pancreatic adenocarcinoma and prospects for screening. Gastroenterol Hepatol (NY) 2010; 6: 246–54.

Goonetilleke

K.S.

, Siriwardena

A.K.

. Systematic review of carbohydrate antigen (CA 19–9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007; 33: 266–70.

Steinberg

. The clinical utility of the CA 19–9 tumor-associated antigen. Am J Gastroenterol 1990; 85: 350–5.

Niederau

, Grendell

J.H.

. Diagnosis of pancreatic carcinoma: imaging techniques and tumor markers. Pancreas 1992; 7: 66–86.

Duffy

M.J.

, Sturgeon

, Lamerz

. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol 2010; 21: 441–7.

Schlieman

M.G.

, Ho

S.H.

, Bold

R.J.

. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003; 138: 951–6.

Gansauge

, Gansauge

, Parker

. CAM 17.1 – a new diagnostic marker in pancreatic cancer. Br J Cancer 1996; 74: 1997–2002.

10.

Banfi

, Zerbi

, Pastori

, Parolini

, Di Carlo

, Bonini

. Behavior of tumor markers CA 19–9, CA 195, CAM 43, CA 242 and TPS in the diagnosis and follow-up of pancreatic cancer. Clin Chem 1993; 39: 420–3.

11.

Haglund

. Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA 19–9 and CEA. Br J Cancer 1986; 54: 897–901.

12.

Zhao

X.Y.

, Yu

S.Y.

, Da

S.P.

. A clinical evaluation of serological diagnosis for pancreatic cancer. World J Gastroenterol 1998; 4: 147–9.

13.

Pasanen

P.A.

, Eskelinen

, Partanen

, Pikkarainen

, Penttilä

, Alhava

. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score. Br J Cancer 1994; 69: 562–5.

14.

Dunlop

R.J.

, Campbell

C.W.

. Cytokines and advanced cancer. J Pain Sympt Manage 2000; 20: 214–32.

15.

Smith

M.A.

, Court

, Smith

J.G.

. Stem cell factor: laboratory and clinical aspects. Blood Rev 2001; 15: 191–7.

16.

Mroczko

, Szmitkowski

. Hematopoietic cytokines as tumor markers. Clin Chem Lab Med 2004; 42: 1347–54.

17.

Berdel

W.E.

, Danhauser

R.S.

, Oberberg

, Zafferani

. Effects of hematopoietic growth factors on malignant nonhematopoietic cells. Semin Oncol 1992; 19: 41–5.

18.

Esposito

, Kleeff

, Bischoff

S.C.

. The stem cell factor-c-kit system and mast cells in human pancreatic cancer. Lab Invest 2002; 82: 1481–92.

19.

Turner

A.M.

, Zsebo

K.M.

, Martin

, Jacobsen

F.W.

, Bennett

L.G.

, Broudy

V.C.

. Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors. Blood 1992; 80: 374–81.

20.

Miyagawa

, Chiba

, Shibuya

. Frequent expression of receptors for granulocyte-macrophage colony-stimulating factor on human nonhematopoietic tumor cell lines. J Cell Physiol 1990; 143: 483–7.

21.

Tani

, Ozawa

, Ogura

. Expression of granulocyte and granulocyte macrophage colony-stimulating factors by human non-hematopoietic tumor cells. Growth Factors 1990; 3: 325–31.

22.

Pei

X.H.

, Nakanishi

, Takayama

, Bai

, Hara

. Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells. Br J Cancer 1999; 79: 40–6.

23.

Suzuki

, Ohwada

, Sato

, Nagatomo

. Serum level of macrophage colony-stimulating factor as a marker for gynecologic malignancies. Oncology 1995; 52: 128–33.

24.

Mc Dermott

R.S.

, Deneux

, Mosseri

. Circulating macrophage colony-stimulating factor as a marker of tumor progression. E Cytokine Network 2002; 13: 121–7.

25.

Freelove

, Walling

A.D.

. Pancreatic cancer: diagnosis and management. Am Fam Physician 2006; 73: 485–92.

26.

Lamerz

. Role of tumour markers, cytogenetics? Ann Oncol 1999; 10 Suppl 4: 145–9.

27.

Mroczko

, Szmitkowski

, Wereszczynska-Siemiatkowska

, Okulczyk

. Stem cell factor (SCF) and interleukin 3 (IL-3) in the sera of patients with colorectal cancer. Dig Dis Sci 2005; 50: 1019–24.

28.

Mroczko

, Szmitkowski

, Niklinski

. Stem cell factor and granulocyte-macrophage-colony stimulating factor as candidates for tumours markers for non-small-cell lung cancer. Clin Chem Lab Med 1999; 37: 959–62.

29.

Mroczko

, Szmitkowski

, Okulczyk

. Hematopoietic growth factors in colorectal cancer patients. Clin Chem Lab Med 2003; 41: 646–51.

30.

Whicher

J.T.

, Banks

R.E.

. Cytokines as tumour markers. Scand J Clin Lab Invest 1995; 55: 122–44.

31.

Mroczko

, Groblewska

, Wereszczynska-Siemiatkowska

. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis. Clin Chim Acta 2007; 380: 208–12.

32.

Lukaszewicz-Zajac

, Mroczko

, Kozlowski

, Niklinski

, Laudanski

, Szmitkowski

. Clinical significance of serum macrophage-colony stimulating factor (M-CSF) in esophageal cancer patients and its comparison with classical tumor markers. Clin Chem Lab Med 2010; 48: 1467–73.

33.

Mroczko

, Szmitkowski

, Wereszczynska-Siemiatkowska

, Jurkowska

. Stem cell factor and macrophage-colony stimulating factor in patients with pancreatic cancer. Clin Chem Lab Med 2004; 42: 256–60.

34.

Mroczko

, Szmitkowski

, Wereszczynska-Siemiatkowska

, Jurkowska

. Hematopoietic cytokines in the sera of patients with pancreatic cancer. Clin Chem Lab Med 2005; 43: 146–50.

35.

Groblewska

, Mroczko

, Wereszczynska-Siemiatkowska

. Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients. Clin Chem Lab Med 2007; 45: 30–4.